Genmab AS (GMAB) - Total Assets
Based on the latest financial reports, Genmab AS (GMAB) holds total assets worth $12.84 Billion USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore long-term investment intensity of Genmab AS to see how much of total assets are deployed in long-term investments.
Genmab AS - Total Assets Trend (2002–2025)
This chart illustrates how Genmab AS's total assets have evolved over time, based on quarterly financial data. Check Genmab AS (GMAB) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Genmab AS - Asset Composition Analysis
Current Asset Composition (December 2025)
Genmab AS's total assets of $12.84 Billion consist of 22.4% current assets and 77.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 13.3% |
| Accounts Receivable | $1.15 Billion | 9.0% |
| Inventory | $17.96 Million | 0.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $9.10 Billion | 70.9% |
| Goodwill | $354.19 Million | 2.8% |
Asset Composition Trend (2002–2025)
This chart illustrates how Genmab AS's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Genmab AS market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Genmab AS's current assets represent 22.4% of total assets in 2025, a decrease from 89.6% in 2002.
- Cash Position: Cash and equivalents constituted 13.3% of total assets in 2025, down from 16.0% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 72.0% of total assets, an increase from 4.0% in 2002.
- Asset Diversification: The largest asset category is intangible assets at 70.9% of total assets.
Genmab AS Competitors by Total Assets
Key competitors of Genmab AS based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $146.48 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
|
Hyundai Bioscience Co. Ltd
KQ:048410
|
Korea | ₩130.74 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥772.57 Million |
|
Lifecome Biochemistry Co Ltd
SHE:002868
|
China | CN¥773.72 Million |
Genmab AS - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.02 | 5.25 | 15.42 |
| Quick Ratio | 2.01 | 5.24 | 15.42 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.45 Billion | $22.55 Billion | $18.64 Billion |
Genmab AS - Advanced Valuation Insights
This section examines the relationship between Genmab AS's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.92 |
| Latest Market Cap to Assets Ratio | 1.26 |
| Asset Growth Rate (YoY) | -72.0% |
| Total Assets | $12.84 Billion |
| Market Capitalization | $16.23 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Genmab AS's assets above their book value (1.26x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Genmab AS's assets decreased by 72.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Genmab AS (2002–2025)
The table below shows the annual total assets of Genmab AS from 2002 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $12.84 Billion | -71.96% |
| 2024-12-31 | $45.81 Billion | +29.82% |
| 2023-12-31 | $35.29 Billion | +17.17% |
| 2022-12-31 | $30.12 Billion | +22.30% |
| 2021-12-31 | $24.63 Billion | +16.48% |
| 2020-12-31 | $21.14 Billion | +39.61% |
| 2019-12-31 | $15.14 Billion | +78.99% |
| 2018-12-31 | $8.46 Billion | +28.14% |
| 2017-12-31 | $6.60 Billion | +26.05% |
| 2016-12-31 | $5.24 Billion | +34.23% |
| 2015-12-31 | $3.90 Billion | +36.13% |
| 2014-12-31 | $2.87 Billion | +65.56% |
| 2013-12-31 | $1.73 Billion | +2.28% |
| 2012-12-31 | $1.69 Billion | +8.21% |
| 2011-12-31 | $1.56 Billion | -36.96% |
| 2010-12-31 | $2.48 Billion | +11.71% |
| 2009-12-31 | $2.22 Billion | -31.83% |
| 2008-12-31 | $3.26 Billion | -17.68% |
| 2007-12-31 | $3.96 Billion | +119.37% |
| 2006-12-31 | $1.80 Billion | +31.68% |
| 2005-12-31 | $1.37 Billion | +7.75% |
| 2004-12-31 | $1.27 Billion | +7.78% |
| 2003-12-31 | $1.18 Billion | -25.46% |
| 2002-12-31 | $1.58 Billion | -- |
About Genmab AS
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervi… Read more